Heparin-induced thrombocytopenia: A tremendous opportunity for randomization

Austin Lammers, Thomas DeLoughery, Vinay Prasad

Research output: Contribution to journalArticlepeer-review


Heparin-induced thrombocytopenia and thrombosis (HITT) is both life-threatening with a complex immune-mediated process and clinically challenging to diagnose and treat. What further complicates matters is that thrombocytopenia is a frequently encountered laboratory value but rarely results in clinical signs of HITT. Decades into its initial description, we have anticoagulants with a small therapeutic index and associated high cost. The diagnosis is sometimes equivocal given our current laboratory diagnostics, and can take days to confirm. Furthermore, prior studies that resulted in the approval of anticoagulants for the treatment of heparin-induced thrombocytopenia have been imperfectly designed. Further evaluations of patients with HITT could more adequately define these difficult issues.

Original languageEnglish (US)
Pages (from-to)272-274
Number of pages3
JournalBlood Coagulation and Fibrinolysis
Issue number3
StatePublished - Apr 1 2017


  • anticoagulants
  • argatroban
  • bivalirudin
  • diagnostic criteria
  • heparin-induced thrombocytopenia and thrombosis
  • heparin-induced thrombocytopenia-safe anticoagulants
  • randomized trials
  • the need for RCTs

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Heparin-induced thrombocytopenia: A tremendous opportunity for randomization'. Together they form a unique fingerprint.

Cite this